2013 International Conference on Diabetes and Metabolism & 5th Asian Association for the Study of Diabetes

6 ~ 9 November 2013
Grand Hilton Seoul Hotel, Seoul, Korea

Abstract submission: 1 July ~ 6 September 2013
Pre-registration: 1 July ~ 30 September 2013

http://icdm2013.diabetes.or.kr

Plenary lectures
PL-1 Douglas C. Wallace
University of Pennsylvania, USA

PL-2 Roger Davis
University of Massachusetts, USA

PL-3 Nobuya Inagaki
Kyoto University, Japan
Contents

04. Organization

05. Program at a glance

12. Scientific program
   - Plenary / Presidential lectures
   - Main symposia
   - Corporate symposia

24. Social program

25. Floor plan

26. General information
   - Registration
   - Call for abstracts
   - Travel grant
   - Accommodation
   - Transportation

33. Seoul attractions
ICDM 2013 & 5th AASD Organizing Committee

- Chairman  Bong Yun Cha
- Secretary general  Hyuk-Sang Kwon
- Government liaison  Joong-Hee Kang
- Public relation  Sung-Rae Kim
- Auditor  Ho Sang Shon, Kyung Wan Min

- Co-Chairman  Hong-Sun Baek
- Scientific program  Kyung Soo Ko
- Education  Hong Woo Nam
- Treasurer  Sang-Ah Chang

- Secretary general  Hyuk-Sang Kwon
- Chairman  Bong Yun Cha

Organization

5th AASD Scientific Advisory Board

- President  Hong Kyu Lee, Korea
- Members  Bong Yun Cha, Korea
  Nigishi Hotta, Japan
  Welpeing Jia, China
  Moon Kyu Lee, Korea
  Yutaka Ueki, Japan
  Daisuke Yabe, Japan
  Nam Han Cho, Korea
  Nobuya Inagaki, Japan
  Takashi Kadowaki, Japan
  Ronald Ma, Hong Kong
  Wayne H.H. Sheu, Taiwan
  Alice Wong, Hong Kong
  Wenyling Yang, China

ICDM 2013 & 5th AASD Scientific Program Committee

- Chair  Kyung Soo Ko
- Secretary  Eun Hee Koh
- Members  Jin Han
  In Kyung Jeong
  Dae Jung Kim
  Hyuk Sang Kwon
  Dae-Kyu Song
  Eun Gyoung Hong
  Heung Yong Jih
  Jaetaek Kim
  Jueng Hyeun Noh
  Kyu Chang Won

ICDM 2013 - International Advisory Board

- Linong Ji, China
- Kevin Tan Eng Kiat, Singapore
- Waninee Mityanant, Thailand
- Paul Williams, Australia
- Vivian Fonseca, USA
- Takashi Kadowaki, Japan
- Moon Kyu Lee, Korea
- Wayne H. H. Sheu, Chinese Taipei

ICDM 2013 - Local Advisory Board

- Dong Seop Choi
- Kap Bum Huh
- Jin Woo Kim
- Yong Ki Kim
- Sun Woo Kim
- Tai Hee Lee
- Ho Young Son
- Young Ki Choi
- Sung Koo Kang
- Kwang Won Kim
- Young Kun Kim
- Hong Kyu Lee
- Hun Ki Min
- Soon Hyun Shin

ICDM 2013 & 5th AASD Scientific Program Committee

- Welcome reception
- Special interest group session
- Oral presentation
- Poster presentation
- Presidential / Plenary lecture
- Satellite / Breakout
# Program at a glance 7 November 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>Breakfast symposium 1</td>
</tr>
<tr>
<td>08:00</td>
<td>Breakfast symposium 2</td>
</tr>
<tr>
<td>09:00</td>
<td>Opening ceremony</td>
</tr>
<tr>
<td>10:00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>11:00</td>
<td>Luncheon symposium 1</td>
</tr>
<tr>
<td>12:00</td>
<td>Luncheon symposium 2</td>
</tr>
<tr>
<td>13:00</td>
<td>Luncheon symposium 3</td>
</tr>
<tr>
<td>14:00</td>
<td>Poster presentation</td>
</tr>
<tr>
<td>15:00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>16:00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>17:00</td>
<td>Presidential dinner (invitation only)</td>
</tr>
<tr>
<td>18:00</td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
</tr>
</tbody>
</table>

## Room Assignments

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Floor</td>
<td>Convention center 4F</td>
<td>Convention center 4F</td>
<td>Convention center 3F</td>
<td>Convention center 3F</td>
<td>Convention center 3F</td>
<td>Hotel 2F</td>
<td>Hotel 3F</td>
<td>Hotel 3F</td>
<td>Hotel 2F</td>
<td>Hotel 2F</td>
<td>Hotel 2F</td>
<td>Hotel 2F</td>
</tr>
<tr>
<td>Topic</td>
<td>Clinical diabetes / therapeutics I</td>
<td>Clinical diabetes / therapeutics II</td>
<td>Diabetic complications</td>
<td>Obesity</td>
<td>Insulin resistance</td>
<td>Education and integrated care</td>
<td>Islet biology</td>
<td>Epidemiology / Genetics</td>
<td>Oral presentation 1</td>
<td>Oral presentation 2</td>
<td>Oral presentation 3</td>
<td>Oral presentation 4</td>
</tr>
</tbody>
</table>

## Symposia Assignments

- **Symposia (ICDM)**: Clinical diabetes / therapeutics I, Clinical diabetes / therapeutics II, Diabetic complications, Obesity, Insulin resistance, Education and integrated care, Islet biology, Epidemiology / Genetics.
- **Symposia (AASD)**: Oral presentation, Poster presentation, Presidential / Plenary lecture.
- **Symposia (ICDM & AASD)**: Oral presentation, Poster presentation, Presidential / Plenary lecture.

## Oral Presentation Assignments

- **Oral presentation**: Oral presentation 1, Oral presentation 2, Oral presentation 3, Oral presentation 4.
# Program at a glance 8 November 2013

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Floor</td>
<td>Convention center 4F</td>
<td>Convention center 4F</td>
<td>Convention center 3F</td>
<td>Convention center 3F</td>
<td>Hotel 2F</td>
<td>Hotel 2F</td>
<td>Hotel 2F</td>
<td>Hotel 2F</td>
<td>Hotel 2F</td>
<td>Hotel 2F</td>
<td>Hotel 2F</td>
<td>Hotel 2F</td>
</tr>
<tr>
<td>Topic</td>
<td>Clinical diabetes / therapeutics I</td>
<td>Clinical diabetes / therapeutics II</td>
<td>Diabetic complications</td>
<td>Obesity</td>
<td>Insulin resistance</td>
<td>Education and integrated care</td>
<td>Islet biology</td>
<td>Epidemiology / Genetics</td>
<td>Oral presentation 1</td>
<td>Oral presentation 2</td>
<td>Oral presentation 3</td>
<td>Oral presentation 4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>Breakfast symposium 3</td>
</tr>
<tr>
<td>07:00</td>
<td>Breakfast symposium 4</td>
</tr>
<tr>
<td>07:00</td>
<td>Breakfast symposium 5</td>
</tr>
<tr>
<td>08:00</td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>E25: Updates of anti-diabetic agents (ICDM)</td>
</tr>
<tr>
<td>09:00</td>
<td>C25: Clinical Diabetes (Committee of clinical practice guideline) (ICDM)</td>
</tr>
<tr>
<td>09:00</td>
<td>DK3: Diabetes foot (ICDM &amp; AASD)</td>
</tr>
<tr>
<td>09:00</td>
<td>OR3: Hypothalamic regulation of obesity (ICDM &amp; AASD)</td>
</tr>
<tr>
<td>09:00</td>
<td>R3: Autophagy in Insulin resistance (ICDM)</td>
</tr>
<tr>
<td>09:00</td>
<td>R2: Diet, advanced glycation endproducts (AGE) and diabetes (ICDM)</td>
</tr>
<tr>
<td>10:00</td>
<td>R1: Microvascular complication 1 (AASD)</td>
</tr>
<tr>
<td>10:00</td>
<td>OP5: Microvascular complication 2 (AASD)</td>
</tr>
<tr>
<td>10:00</td>
<td>OP7: Metabolic syndrome</td>
</tr>
<tr>
<td>10:00</td>
<td>OP8: Epidemiology</td>
</tr>
<tr>
<td></td>
<td>Coffee break</td>
</tr>
<tr>
<td>11:00</td>
<td>E31: Presidential lecture (AASD)</td>
</tr>
<tr>
<td>11:00</td>
<td>PL2: Plenary lecture 2 (ICDM)</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>CDP7: Measurement of insulin resistance and secretion in diabetes clinic (ICDM)</td>
</tr>
<tr>
<td>15:00</td>
<td>D1: Upcoming new class of diabetic medications; SGLT2 inhibitor (AASD)</td>
</tr>
<tr>
<td>15:00</td>
<td>D1a: Diabetic retinopathy (ICDM)</td>
</tr>
<tr>
<td>15:00</td>
<td>OM4: Lipid metabolites and metabolism (ICDM)</td>
</tr>
<tr>
<td>15:00</td>
<td>R4: Adipose tissue inflammation (AASD)</td>
</tr>
<tr>
<td>15:00</td>
<td>R7a: Endocrine disrupting chemicals and diabetes mellitus (ICDM)</td>
</tr>
<tr>
<td>15:00</td>
<td>S2:</td>
</tr>
<tr>
<td>15:00</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
</tr>
</tbody>
</table>

Symposia (ICDM) Symposia (AASD) Symposia (ICDM & AASD) Satellite / Breakfast
# Program at a glance 9 November 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>Breakfast symposium 6</td>
</tr>
<tr>
<td>08:00</td>
<td>Breakfast symposium 7</td>
</tr>
<tr>
<td>09:00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10:00</td>
<td>AASD awards (AASD)</td>
</tr>
<tr>
<td>11:00</td>
<td>Luncheon symposium 9</td>
</tr>
<tr>
<td>12:00</td>
<td>Luncheon symposium 10</td>
</tr>
<tr>
<td>13:00</td>
<td>Luncheon symposium 11</td>
</tr>
<tr>
<td>14:00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>15:00</td>
<td>Large clinical studies in Asia (AASD)</td>
</tr>
<tr>
<td>16:00</td>
<td>Closing ceremony</td>
</tr>
<tr>
<td>17:00</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
</tr>
</tbody>
</table>
Plenary lecture I (ICDM)  
Thursday, 7 November 13:10 ~ 14:00 / Convention hall A&B&C, 4F

Douglas C. Wallace  
University of Pennsylvania, USA

PL1  
TBD

Plenary lecture II (ICDM)  
Friday, 8 November 11:20 ~ 12:10 / Convention hall A&B&C, 4F

Roger Davis  
University of Massachusetts, USA

PL2  
Metabolic stress signaling by the JNK pathway

Plenary lecture III (AASD)  
Saturday, 9 November 13:00~14:00 / Convention hall A&B&C, 4F

Nobuya Inagaki  
Kyoto University, Japan

PL3  
Incretin and islet pathophysiology

Presidential lecture (KDA) (ICDM)  
Thursday, 7 November 09:30 ~ 09:50 / Convention hall A&B&C, 4F

Bong Yun Cha  
The Catholic University, Korea

PR1  
Diabetes in Korea 2013

Presidential lecture (AASD)  
Friday, 8 November 11:00 ~ 11:20 / Convention hall A&B&C, 4F

Hong Kyu Lee  
Eulji University, Korea

PR2  
Revisiting syndrome X of Reaven from mitochondrial perspectives
Thursday, 7 November

**Clinical diabetes therapeutics I**

**CD1 Non-invasive diagnostic tool for detecting cardiovascular disease in diabetes (ICDM)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD1-1</td>
<td>The current position of MDCT in research for patients with diabetes</td>
<td>Sung Hee Choi (Seoul National University, Korea)</td>
</tr>
<tr>
<td>CD1-2</td>
<td>The role of coronary artery calcium score on the detection of subclinical atherosclerosis in metabolic diseases</td>
<td>Eun-Jung Rhee (Sungkyunkwan University, Korea) and Sung Eun Kim (Korea University, Korea)</td>
</tr>
<tr>
<td>CD1-3</td>
<td>Molecular imaging in cardiovascular and metabolic research</td>
<td>Hee-Sook Jun (Gachon University, Korea) and Susumu Seino (Kobe University, Japan)</td>
</tr>
</tbody>
</table>

**Clinical diabetes therapeutics II**

**CD2 Pleiotrophic effects of incretins (AASD)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD2-1</td>
<td>Young Min Cho (Seoul National University, Korea) and Dae Ho Lee (Wonkwang University, Korea)</td>
<td></td>
</tr>
<tr>
<td>CD2-2</td>
<td>Non-glycemic effect of DPP4/CD26</td>
<td>Norio Harada (Kyoto University, Japan)</td>
</tr>
<tr>
<td>CD2-3</td>
<td>GIP and high-fat induced obesity</td>
<td>Ronald C.W. Ma (The Chinese University of Hong Kong, Hong Kong) and Hirohito Sone (Niigata University, Japan)</td>
</tr>
</tbody>
</table>

**Diabetic complications**

**DC1 Diabetic nephropathy (ICDM)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>DC1-1</td>
<td>The current position of MDCT in research for patients with diabetes</td>
<td>Sung Hee Choi (Seoul National University, Korea)</td>
</tr>
<tr>
<td>DC1-2</td>
<td>The role of coronary artery calcium score on the detection of subclinical atherosclerosis in metabolic diseases</td>
<td>Eun-Jung Rhee (Sungkyunkwan University, Korea) and Sung Eun Kim (Korea University, Korea)</td>
</tr>
<tr>
<td>DC1-3</td>
<td>Molecular imaging in cardiovascular and metabolic research</td>
<td>Hee-Sook Jun (Gachon University, Korea) and Susumu Seino (Kobe University, Japan)</td>
</tr>
</tbody>
</table>

**OM1 Current status of bariatric surgery in Asia (AASD)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>OM1-1</td>
<td>Go Wakabayashi (Iwate Medical University, Japan) and Young Gyu Ko (Seoul National University, Korea)</td>
<td></td>
</tr>
<tr>
<td>OM1-2</td>
<td>Yujiro Amano (Soochunhyang University, Korea) and Kyung-Yul Hur (Yonsei University, Korea)</td>
<td></td>
</tr>
<tr>
<td>OM1-3</td>
<td>Ender Kwock-wai Ng (The Chinese University of Hong Kong, Hong Kong)</td>
<td></td>
</tr>
</tbody>
</table>

**Insulin resistance**

**IR1 Insulin resistance in muscle (ICDM & AASD)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>IR1-1</td>
<td>MG53 is a therapeutic target protein for insulin resistance</td>
<td>Young Gyu Ko (Korea University, Korea)</td>
</tr>
<tr>
<td>IR1-2</td>
<td>MMF is a myokine that regulates glucose transport induced by insulin and AICAR in skeletal muscle</td>
<td>Nobuharu Fujii (Tokyo Metropolitan University, Japan) and Gary Sweeney (York University, Canada)</td>
</tr>
<tr>
<td>IR1-3</td>
<td>Mechanisms regulating insulin sensitivity in skeletal muscle</td>
<td>Catherine Kim (University of Michigan, USA) and Nobuharu Fujii (Tokyo Metropolitan University, Japan)</td>
</tr>
</tbody>
</table>

**Epidemiology / genetics**

**EG1 Diabetes in Asia (AASD)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>EG1-1</td>
<td>Type 2 diabetes in East Asians: similarities and differences</td>
<td>Ronald C.W. Ma (The Chinese University of Hong Kong, Hong Kong) and Nobuharu Fujii (Tokyo Metropolitan University, Japan)</td>
</tr>
<tr>
<td>EG1-2</td>
<td>Prediction and risk assessment of diabetes and its complications in Japan</td>
<td>Duk-Woo Park (University of Ulsan, Korea)</td>
</tr>
</tbody>
</table>

**CD4 Gestational diabetes update (ICDM)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4-1</td>
<td>Adopting of IADPSG criteria for GDM in U.S.</td>
<td>Sun Min Kim (Seoul National University, Korea)</td>
</tr>
<tr>
<td>CD4-2</td>
<td>MODY and gestational diabetes</td>
<td>Soo-Heon Kwak (Seoul National University, Korea) and Seung-Hyun Ko (The Catholic University, Korea)</td>
</tr>
<tr>
<td>CD4-3</td>
<td>Prediction and risk assessment of gestational diabetes</td>
<td>Seung-Hyun Ko (The Catholic University, Korea)</td>
</tr>
</tbody>
</table>

**Iodet biology**

**IB1 Beta cell pathophysiology and regeneration (AASD)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>IB1-1</td>
<td>Pancreatic beta-cell replenishment</td>
<td>Hee-Sook Jun (Gachon University, Korea) and Sung Eun Kim (Korea University, Korea)</td>
</tr>
<tr>
<td>IB1-2</td>
<td>Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2</td>
<td>Norio Harada (Kyoto University, Japan) and Susumu Seino (Kobe University, Japan)</td>
</tr>
<tr>
<td>IB1-3</td>
<td>TBD</td>
<td>Joo Hun Ha (Kyung Hee University, Korea) and Keun-Gyu Park (Kyungpook National University, Korea)</td>
</tr>
</tbody>
</table>

**EC1 Clinical practice of multidisciplinary team approach (ICDM)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>EC1-1</td>
<td>Exercise benefit beyond glucose control</td>
<td>Young Min Cho (Seoul National University, Korea) and Hee-Sook Jun (Gachon University, Korea)</td>
</tr>
<tr>
<td>EC1-2</td>
<td>A cognitive-behavioral approach to diabetes</td>
<td>Sun Hee Choi (Seoul National University, Korea) and Susumu Seino (Kobe University, Japan)</td>
</tr>
<tr>
<td>EC1-3</td>
<td>Team care for the prevention of hypoglycemia</td>
<td>Kangnam Sacred Heart Hospital, Korea and Eulji University, Korea</td>
</tr>
</tbody>
</table>

**CD3 Diabetes and cancer (ICDM)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD3-1</td>
<td>Epidemiology of cancer in diabetes</td>
<td>Kyung Wan Min (Eulji University, Korea) and Sung Eun Kim (Korea University, Korea)</td>
</tr>
<tr>
<td>CD3-2</td>
<td>AMPK as a medication target for diabetes and cancer</td>
<td>Soo-Heon Kwak (Seoul National University, Korea) and Duk-Woo Park (University of Ulsan, Korea)</td>
</tr>
<tr>
<td>CD3-3</td>
<td>Modulation of glycose metabolism in cancer : as a potential cancer therapy</td>
<td>Joo Hun Ha (Kyung Hee University, Korea) and Young-Gyu Ko (Korea University, Korea)</td>
</tr>
</tbody>
</table>

**OM1 Current status of bariatric surgery in Asia (AASD)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>OM1-1</td>
<td>Current status of bariatric surgery in Asia</td>
<td>Sung Eun Kim (Korea University, Korea) and Insoo Lee (Seoul National University, Korea)</td>
</tr>
<tr>
<td>OM1-2</td>
<td>Bariatric to metabolic surgery</td>
<td>Eun-Jung Rhee (Sungkyunkwan University, Korea) and Sung Eun Kim (Korea University, Korea)</td>
</tr>
<tr>
<td>OM1-3</td>
<td>Bariatric surgery in Hong Kong</td>
<td>Joo Hun Ha (Kyung Hee University, Korea) and Keun-Gyu Park (Kyungpook National University, Korea)</td>
</tr>
</tbody>
</table>

**IR1 Insulin resistance in muscle (ICDM & AASD)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>IR1-1</td>
<td>MG53 is a therapeutic target protein for insulin resistance</td>
<td>Young Gyu Ko (Korea University, Korea) and Nobuharu Fujii (Tokyo Metropolitan University, Japan)</td>
</tr>
<tr>
<td>IR1-2</td>
<td>MMF is a myokine that regulates glucose transport induced by insulin and AICAR in skeletal muscle</td>
<td>Gary Sweeney (York University, Canada) and Catherine Kim (University of Michigan, USA)</td>
</tr>
<tr>
<td>IR1-3</td>
<td>Mechanisms regulating insulin sensitivity in skeletal muscle</td>
<td>Catherine Kim (University of Michigan, USA) and Nobuharu Fujii (Tokyo Metropolitan University, Japan)</td>
</tr>
<tr>
<td>Session</td>
<td>Title</td>
<td>Details</td>
</tr>
<tr>
<td>---------</td>
<td>--------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Diabetic complications</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DC2</strong></td>
<td>Mechanisms of cardiovascular injury in diabetes (ICDM &amp; AASD)</td>
<td>Thursday, 7 November 16:00~17:30</td>
</tr>
<tr>
<td><strong>DC2-1</strong></td>
<td>Diabetic cardiomyopathy; clinical implications</td>
<td></td>
</tr>
<tr>
<td><strong>DC2-2</strong></td>
<td>Metabolitomin (metabolite-mimic) protects diabetic cardiomyopathy: evidence, mechanisms and potential clinical application</td>
<td></td>
</tr>
<tr>
<td><strong>DC2-3</strong></td>
<td>Role of angiotensin II—RANKL pathway in cardiovascular complication</td>
<td></td>
</tr>
<tr>
<td><strong>Obesity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>OM2</strong></td>
<td>Pathogenesis in non-alcoholic steatohepatitis (ICDM)</td>
<td>Thursday, 7 November 16:00~17:30</td>
</tr>
<tr>
<td><strong>OM2-1</strong></td>
<td>Role of NPC1L1 (niemann-pick C1-like 1) in preventing hepatic steatosis</td>
<td></td>
</tr>
<tr>
<td><strong>OM2-2</strong></td>
<td>Novel regulators in the development of non-alcoholic steatohepatitis</td>
<td></td>
</tr>
<tr>
<td><strong>OM2-3</strong></td>
<td>Cholesterol and sphingolipids in nonalcoholic fatty liver disease</td>
<td></td>
</tr>
<tr>
<td><strong>Insulin resistance</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IR2</strong></td>
<td>Understanding lipid metabolism to reduce insulin resistance (AASD)</td>
<td></td>
</tr>
<tr>
<td><strong>IR2-1</strong></td>
<td>Dexamet, a new link between glucocorticoid and insulin/IGF-1 signaling in adipocytes</td>
<td></td>
</tr>
<tr>
<td><strong>IR2-2</strong></td>
<td>Inhibition of lipid biosynthesis increases energy expenditure and insulin sensitivity</td>
<td></td>
</tr>
<tr>
<td><strong>IR2-3</strong></td>
<td>Pathophysiological roles of Adiponectin in the regulation of insulin sensitivity</td>
<td></td>
</tr>
<tr>
<td><strong>Education and integrated care</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EC2</strong></td>
<td>Diet, advanced glycation endproducts (AGE) and diabetes (ICDM)</td>
<td>Friday, 8 November 09:00~10:30</td>
</tr>
<tr>
<td><strong>EC2-1</strong></td>
<td>Comparison of AGES produced by heat process and various cooking methods</td>
<td></td>
</tr>
<tr>
<td><strong>EC2-2</strong></td>
<td>Dietary AGE, inflammation and diabetes</td>
<td></td>
</tr>
<tr>
<td><strong>EC2-3</strong></td>
<td>Comparison of AGES produced by heat process and various cooking methods</td>
<td></td>
</tr>
<tr>
<td><strong>Diabetic complications</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DC3</strong></td>
<td>Diabetes foot (ICDM &amp; AASD)</td>
<td>Friday, 8 November 09:00~10:30</td>
</tr>
<tr>
<td><strong>DC3-1</strong></td>
<td>Epidemiology of diabetic foot</td>
<td></td>
</tr>
<tr>
<td><strong>DC3-2</strong></td>
<td>Diagnosis and management of vasculopathy in diabetic foot</td>
<td></td>
</tr>
<tr>
<td><strong>DC3-3</strong></td>
<td>Management principal of diabetic foot ulcers</td>
<td></td>
</tr>
<tr>
<td><strong>Obesity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>OM3</strong></td>
<td>Hypothalamic regulation of obesity (ICDM &amp; AASD)</td>
<td>Friday, 8 November 09:00~10:30</td>
</tr>
<tr>
<td><strong>OM3-1</strong></td>
<td>Hypothalamic melanocortin receptor 4 signaling in control of obesity</td>
<td></td>
</tr>
<tr>
<td><strong>OM3-2</strong></td>
<td>CNS-mediated control of energy and mental homeostasis; functional roles of Sf-1 in the VMH</td>
<td></td>
</tr>
<tr>
<td><strong>OM3-3</strong></td>
<td>Role of orexin in the hypothalamic regulation of energy homeostasis</td>
<td></td>
</tr>
<tr>
<td><strong>Insulin resistance</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IR3</strong></td>
<td>Autophagy in insulin resistance (ICDM)</td>
<td>Friday, 8 November 09:00~10:30</td>
</tr>
<tr>
<td><strong>IR3-1</strong></td>
<td>Coordinated regulation of autophagy by energy-sensing machineries</td>
<td></td>
</tr>
<tr>
<td><strong>IR3-2</strong></td>
<td>Autophagy deficiency in insulin target tissues leads to protection from obesity and insulin resistance by inducing FGFR1, a “Misokine”</td>
<td></td>
</tr>
<tr>
<td><strong>IR3-3</strong></td>
<td>Adipose tissue autophagy in obesity – contributes to or protect from morbidity?</td>
<td></td>
</tr>
<tr>
<td><strong>Education and integrated care</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MDIA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MDIA (AASD)</strong></td>
<td>Friday, 8 November 09:00~10:30</td>
<td>Grand ballroom B,C</td>
</tr>
<tr>
<td><strong>MD1</strong></td>
<td>Prediction of type 2 diabetes in women with a history of gestational diabetes using a genetic risk score</td>
<td></td>
</tr>
<tr>
<td><strong>MD2</strong></td>
<td>Genetic polymorphisms of PCSK9 on chromosome 10 QTL are associated with glucose homeostasis and progression to type 2 diabetes in a Chinese population</td>
<td></td>
</tr>
<tr>
<td><strong>MD3</strong></td>
<td>Activation of heat shock response improves metabolic profiles in type 2 diabetes</td>
<td></td>
</tr>
<tr>
<td><strong>MD4</strong></td>
<td>Genome-wide association study in a Chinese population identifies a novel locus for T2 DM</td>
<td></td>
</tr>
</tbody>
</table>
Scientific program

Main symposia

**Clinical diabetes therapeutics I**

*CD7* Measurement of insulin resistance and secretion in diabetes clinic (ICDM)  
**CD7-1** Insulin resistance: anthropometric measurement  
**Dae Jung Kim**  
Aju University, Korea  
**CD7-2** Insulin resistance: biochemical and dynamic tests  
**Hye Jin Lee**  
Ewha Womans University, Korea  
**CD7-3** TBD

Others

*OT1* Upcoming new class of diabetic medication; SGLT2 inhibitor (AASD)

**OT1-1** Overview on sodium-glucose co-transporter 2 (SGLT2) inhibitors in glucose homeostasis  
**Kyoog Ah Kim**  
Dongguk University, Korea  
**OT1-2** TBD

**OT1-3** SGLT2 inhibitors: a novel and important new class of antihyperglycemic agent

**Diabetic complications**

*DC4* Diabetic retinopathy (ICDM)  
**DC4-1** Inflammatory basis of diabetic retinopathy  
**Timothy Kern**  
Case Western Reserve University, USA  
**DC4-2** Treatments for diabetic retinopathy: a double-edged sword  
**Dong Ho Park**  
Kyungpook National University, Korea  
**In Boom Kim**  
The Catholic University, Korea  
**DC4-3** Therapeutic targets in diabetic retinopathy: anti-angiogenesis, anti-inflammatory and neuron protection

**Obesity**

*OM4* Lipid metabolites and metabolism (ICDM)  
**OM4-1** Application of bioactive phospholipid profiling: with an emphasis on low level lipids  
**Hyun Joo Yoo**  
University of Ulsan, Korea  
**OM4-2** Regulation of hepatic glucose and fatty acid metabolism by sphingosine 1-phosphate  
**Tae Sik Park**  
Gachon University, Korea  
**OM4-3** Deficiency in sphingolipid de novo synthesis impairs cell polarity  
**Xian Cheng Jiang**  
SUNY Downstate Medical Center, USA

Insulin resistance

*IR4* Adipose tissue inflammation (AASD)  
**IR4-1** Adipose OXPHOS deficiency and insulin resistance  
**Min Ho Song**  
Chungnam National University, Korea  
**IR4-2** Chronic inflammation and ectopic fat accumulation in the metabolic syndrome  
**Yoshitomo Ogawa**  
Tokyo Medical and Dental University, Japan  
**IR4-3** FGF21 resistance in adipose tissues as a cause of insulin resistance  
**Almin Xu**  
The Chinese University of Hong Kong, Hong Kong

Others

*OT2* Endocrine disrupting chemicals and diabetes mellitus (ICDM)

**OT2-1** Diethylnhexyl phthalates is associated with insulin resistance via oxidative stress in the elderly: a panel study  
**Jin Hee Kim**  
Seoul National University, Korea  
**OT2-2** Persistent organic pollutants and diabetes: what we know and what we don’t know  
**Duk Hee Lee**  
Kyungpook National University, Korea  
**OT2-3** The paradox of progress: environmental disruption of metabolism and the diabetes epidemic  
**Robert Sargsis**  
University of Chicago, USA

**AIBIS**

*AIBIS I (AASD)*  
**AIBIS-1** Overview on sodium-glucose co-transporter 2 (SGLT2) inhibitors in glucose homeostasis  
**Won Kyung Ho**  
Seoul National University, Korea  
**AIBIS-2** AMPK-mediated KATP channel trafficking is a key mechanism for glucose-dependent regulation of beta cell excitability  
**Yukihiro Fujita**  
Asahikawa Medical University, Japan  
**AIBIS-3** New aspects of short-form GIP  
**Kenneth Cheng**  
The Chinese University of Hong Kong, Hong Kong

**Clinical diabetes therapeutics I**

*CD8* Recent update on CVD risk management in type 2 diabetes (ICDM)  
**CD8-1** What’s new in hypertension management?  
**Sin Gon Kim**  
Korea University, Korea  
**CD8-2** What’s new in lipid management?  
**Chang Boom Lee**  
Hanyang University, Korea  
**CD8-3** What’s new in other risk management?  
**Gwan Pyo Koh**  
Aju University, Korea

**Saturday, 9 November**

Clinical diabetes therapeutics I  
**CD8** Recent update on CVD risk management in type 2 diabetes (ICDM)  
**CD8-1** What’s new in hypertension management?  
**Sin Gon Kim**  
Korea University, Korea  
**CD8-2** What’s new in lipid management?  
**Chang Boom Lee**  
Hanyang University, Korea  
**CD8-3** What’s new in other risk management?  
**Gwan Pyo Koh**  
Aju University, Korea
### Scientific Program

#### Main Symposia

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, 9 November</td>
<td>09:00~10:30</td>
<td>Convention hall B</td>
</tr>
<tr>
<td>Saturday, 9 November</td>
<td>10:30~12:00</td>
<td>Convention hall A</td>
</tr>
<tr>
<td>Saturday, 9 November</td>
<td>12:00~14:30</td>
<td>Convention hall C</td>
</tr>
<tr>
<td>Saturday, 9 November</td>
<td>14:30~16:00</td>
<td>Grand ballroom B,C</td>
</tr>
</tbody>
</table>

### Clinical Diabetes Therapeutics II

**CD9 Providing optimal treatment for type 1 diabetes (ICDM)**
- **CD9-1**: Dose adjustment for normal eating (DAFNE) in the treatment of type 1 diabetes: promoting the 'expert patient'
  - Harold David McIntyre
  - The University of Queensland, Australia
- **CD9-2**: How to provide optimal treatment for Korean children and adolescents with type 1 diabetes
  - Seung Yang
  - Hallym University, Korea
- **CD9-3**: Where are we, what still needs to be done in the management of Korean adults with type 1 diabetes
  - Jae Hyeon Kim
  - Sungkyunkwan University, Korea

**Diabetic Complications**

**DC9 New targets for the treatment of atherosclerosis (ICDM & AASD)**
- **DC9-1**: Mechanosensitive microRNAs in endothelial inflammation and atherosclerosis
  - Han Joong Jo
  - Emory University, USA
- **DC9-2**: Immune cells as a target for the treatment of atherosclerosis
  - Gi Taek Oh
  - Ewha Womans University, Korea
- **DC9-3**: Targeting endothelial senescence for atherosclerosis treatment: an approach based on SIRT1 modification
  - Yu Wang
  - The Chinese University of Hong Kong, Hong Kong

### Obesity

**OM5 Update of obesity treatment (ICDM)**
- **OM5-1**: Lorcaserin, a novel serotonin 2C agonist for the treatment of obesity
  - Sung Rae Kim
  - The Catholic University, Korea
- **OM5-2**: Review of old drugs: phentermine/topiramate combination
  - Seung Joon Oh
  - Kyung Hee University, Korea
- **OM5-3**: New therapies to induce brown adipose tissue
  - Won Jin Kim
  - University of Ulsan, Korea

### Insulin Resistance

**IR5 Adipokines and hepatokines (ICDM)**
- **IR5-1**: Adipose tissue dysfunction contributes to insulin resistance in obesity
  - Matthias Blüher
  - LMZ Diabetes & Endocrinology, Germany
- **IR5-2**: Multiple roles of adipocytokines in metabolic complications
  - Jae Bum Kim
  - Seoul National University, Korea
- **IR5-3**: The role of novel adipokines and hepatokines in metabolic and vascular disease
  - Kyung Mook Choi
  - Sungkyunkwan University, Korea

### Education and Integrated Care

**EC3 Understanding insulin therapy (ICDM)**
- **EC3-1**: Literature review of insulin therapy
  - Chan Yeong Kwak
  - Hallym University, Korea
- **EC3-2**: The appropriateness of the length of insulin needles based on determination of skin and subcutaneous fat thickness in the abdomen and upper arm with patients with type 2 diabetes
  - Moon Sook Hwang
  - Seoul National University, Korea
- **EC3-3**: Right insulin injection practices
  - Kang Hae Sim
  - Samsung Hospital, Korea

### AIBIS

**AIBIS II (AASD)**
- **AIBIS II-1**: Role of endogenous ROS in pancreatic beta cell dysfunction
  - Eri Mukai
  - Chiba University School of Medicine, Japan
- **AIBIS II-2**: J immunology and illustration of islet graft neural plasticity under the kidney capsule
  - Shu-Cheng Tang
  - National Tsing Hua University, Taiwan
- **AIBIS II-3**: Serotonin regulates glucose stimulated insulin secretion from pancreatic β cells during pregnancy
  - Ha Il Kim
  - KAIST, Korea
  - Michael German
  - UCSI, USA

### Clinical Diabetes Therapeutics I

**CD10 Large clinical studies in Asia (AASD)**
- **CD10-1**: Does incretin-based therapy increase the risk of pancreatitis or pancreatic cancer?: Yes
  - Seung Yang
  - Hallym University, Korea
- **CD10-2**: Beta-cell preservation and regeneration after islet transplantation
  - Daisuke Yabe
  - National Medical Center, Japan
- **CD10-3**: New therapies to induce brown adipose tissue
  - Hyun-Sik Kang
  - Samsung Hospital, Korea

### Others

**OT3 Lessons from clinical trials with incretin-based therapies (AASD)**
- **OT3-1**: The metabolic basis of control over skeletal muscle mass
  - Philip J. Atherton
  - University of Nottingham, UK
- **OT3-2**: Effect of yoga on metabolic abnormalities outcomes in middle-aged and older adults with metabolic syndrome
  - Parco M. Shi
  - The Hong Kong Polytechnic University, Hong Kong
- **OT3-3**: Effects of exercise training on hepatic steatosis in high fat diet-induced obese mice
  - Hyun-Sik Kang
  - Sungkyunkwan University, Korea

### Education and Integrated Care

**EC4 Improving diabetes management with exercise (ICDM)**
- **EC4-1**: Role of endogenous ROS in pancreatic beta cell dysfunction
  - Hyun-Sik Kang
  - Samsung Hospital, Korea
- **EC4-2**: Effect of exercise training on hepatic steatosis in high fat diet-induced obese mice
  - Hyun-Sik Kang
  - Sungkyunkwan University, Korea
- **EC4-3**: The best combination of GLP-1 analog
  - Ronnie Aronson
  - LMC Diabetes & Endocrinology
Scientific program

Corporate symposia

Breakfast symposium 1  Sponsored by Lilly
Thursday, 7 November 07:30~08:30 / Convention hall A
BS-01  TBD
Guntram Schernthaner
Rudolfstiftung Hospital, Austria

Breakfast symposium 2  Sponsored by Novartis
Thursday, 7 November 07:30~08:30 / Convention hall A
BS-02
Considerations for managing special populations with diabetes – role of vildagliptin
Mi-Kyung Kim
Inje University, Korea

Breakfast symposium 3  Sponsored by Daewoong
Friday, 8 November 07:30~08:30 / Convention hall A
BS-03
Sitagliptin: optimal choice of DPP-4 inhibitor for patients with T2DM
Sihoon Lee
Gachon University, Korea

Breakfast symposium 4  Sponsored by Boehringer Ingelheim
Friday, 8 November 07:30~08:30 / Convention hall B
BS-04
Differentiating linagliptin from other DPP-4 inhibitors
Seoul National University, Korea

Breakfast symposium 5  Sponsored by Sanofi
Friday, 8 November 07:30~08:30 / Convention hall C
BS-05
What can we do better for the compliance of type 2 diabetic patients
Eun Gyu Young Hong
Hallym University, Korea

Breakfast symposium 6  Sponsored by MSD
Saturday, 9 November 07:30~08:30 / Convention hall A
BS-06
Efficacy and safety of Sitagliptin in T2DM with CKD and beyond glucose control
Hye Jin Yoo
Korea University, Korea

Breakfast symposium 7  Sponsored by JFW
Saturday, 9 November 07:30~08:30 / Convention hall B
BS-07  TBD

Luncheon symposium 1  Sponsored by Astrazeneca
Thursday, 7 November 12:10~13:10 / Convention hall A,B,C
LS-01
Clinical implications of SAVOR TIMI-53 in type 2 diabetes mellitus
Richard E. Gilbert
University of Toronto, Canada

Luncheon symposium 2  Sponsored by CJ
Thursday, 7 November 12:10~13:10 / Emerald hall A, B
LS-02
Initial therapy with VOGMET® in patients with type 2 diabetes
In Kyung Jeong
Kyung Hee University, Korea

Luncheon symposium 3  Sponsored by ChongKunDang
Thursday, 7 November 12:10~13:10 / Grand ballroom A,B,C
LS-03
Lobeglitazone, a novel PPAR-γ agonist with balanced efficacy and safety
Sin Gon Kim
Korea University, Korea

Luncheon symposium 4  Sponsored by Sanofi
Friday, 8 November 12:30~13:30 / Convention hall A
LS-04
Rediscovering the one insulin you know: latest update focused on CV risk & new clinical trial
Eun Seok Kang
Yonsei University, Korea

Luncheon symposium 5  Sponsored by Takeda
Friday, 8 November 12:30~13:30 / Convention hall B
LS-05
Clinical review of alogliptin focus on ENDURE trial
Yukio Tanizawa
Yamaguchi University, Japan

Luncheon symposium 6  Sponsored by Handok
Friday, 8 November 12:30~13:30 / Convention hall C
LS-06  TBD

Luncheon symposium 7  Sponsored by Novonordisk
Friday, 8 November 12:30~13:30 / Emerald hall A, B
LS-07
Intensification of insulin therapy (focus on high ratio premixed insulin)
Chong Hwa Kim
Sejong General Hospital, Korea

Luncheon symposium 8  Sponsored by MSD
Friday, 8 November 12:30~13:30 / Grand ballroom A,B,C
LS-08  TBD
Soo Lim
Seoul National University, Korea

Luncheon symposium 9  Sponsored by BMS
Saturday, 9 November 12:00~13:00 / Grand ballroom A,B,C
LS-09  TBD
Kyu Yeon Hur
Sungkyunkwan University, Korea

Luncheon symposium 10  Sponsored by Astrazeneca
Saturday, 9 November 12:00~13:00 / Emerald hall A, B
LS-10
The atherogenic dyslipidemia of diabetes mellitus: not just a question of LDL-C
Eun-Jung Rhee
Sungkyunkwan University, Korea

Luncheon symposium 11  Sponsored by Jeil
Saturday, 9 November 12:00~13:00 / Grand ballroom A,B,C
LS-11
Eye on Korean data: lipid management in Korean DM patients, AMADEUS study
Sung Rae Kim
The Catholic University, Korea
Social program

Welcome reception
- Date & time: Wednesday 6 November [17:00 – 18:00]
- Place: 2F, Grand ballroom A, B, C

Opening ceremony
- Date & time: Thursday 7 November [09:00 – 09:30]
- Place: 4F, Convention hall A, B, C

Presidential dinner **Invitation only
- Date & time: Thursday 7 November [17:30 – ]
- Place: 2F, Grand ballroom A, B, C
>> A dinner for speakers, session chairs and executive delegates will be hosted by the organizing committee in the middle of congress period.
>> This program is to express gratitude for their contribution to the ICDM & AASD.

Closing ceremony
- Date & time: Saturday 9 November [16:00 – ]
- Place: 4F, Convention hall A, B, C
Registration guidelines

Pre-registration has the advantage of discount. After the deadline it is not available to register.

On-line pre-registration Deadline : 1 July – 30 September 2013
On-site registration : 6 – 9 November 2013
* On-site registration hours are set for :
   Nov. 6 (Wed) 14:00-16:30
   Nov. 7 (Thu) 07:30-17:30
   Nov. 8 (Fri) 07:30-16:30
   Nov. 9 (Sat) 07:30-15:00

Delegates - Healthcare professionals including physicians
Resident / Student registration requires a written letter on their affiliation letterhead, with the statement that the registered person is a resident / student at the time of the conference, to be signed by the registrant’s advisor (Professor, Supervisor, etc.). This letter ought to be sent to the diabetes@kams.or.kr, with a scanned PDF email attachment.

Public health and military doctors’ registration rates are the same of the residents’.

Admission to :
- Opening ceremony and closing ceremony
- Welcome reception
- All scientific sessions
- Sponsored morning, luncheon
- Exhibition area
- Congress kit, program book and abstract book

Category | Pre-registration | On-site registration
--- | --- | ---
| Korean | Foreigner | Korean | Foreigner |
Delegates | Member : KRW 200,000
Non-member : KRW 250,000 | USD 100 | Member : KRW 250,000
Non-member : KRW 300,000 | USD 150
Paramedics | Member : KRW 100,000
Non-member : KRW 150,000 | USD 100 | Member : KRW 150,000
Non-member : KRW 200,000 | USD 200
Residents Students | Participants from Financial Support Countries: USD 50

Payment

- Method: Paying by credit is only available.
- Credit cards: VISA Master card, JCB
** AMEX, UnionPay, etc. are not accepted.
- All service charges on credit card are to be paid by registrants.

Cancellation and refund policy

The organizing committee will refund the registration fee according to the following policy.

From 1 October 2013 registration payment cannot be refunded.
- A request for cancelling registration must be pre-notified in writing to the secretariat by e-mail or fax.
- Cancelling registration by phone is not accepted.
- To transfer registration fee to another is not allowed.

Refunds will be made after the conference. Not be accepted and processed on site at the meeting. If you have any questions regarding the registration, please contact the ICDM 2013 & 5th AASD secretariat.
The scientific program committee invites all interested participants to submit abstracts for the oral or poster presentations. The abstract submission operates based on 100% online system. All abstracts will be reviewed by the scientific program committee and the secretariat will inform submitters of the results via email. Note that the committee may change the preferred presentation type of papers in order to effectively organize the program. Acceptance / rejection of abstracts will be notified to the submitters by September 30, 2013. Authors must register and attend the meeting – A presenting author’s registration must be done by 30 September. After the date, the committee will reject the papers of those who have not registered.

If you want to make onsite registration, inform the secretariat (diabetes@kams.or.kr) in case your research will not be included in the book and program.

**Categories**

- Islet biology / insulin secretion
- Insulin signaling / action
- Integrated physiology / obesity
- Therapeutics of diabetes
- Clinical diabetes
- Epidemiology / genetics
- Macrovascular complications
- Microvascular complications
- Metabolic syndrome & prediabetes
- Behavior, nutrition, education & exercise
- Macrovascular complications
- Microvascular complications
- Metabolic syndrome & prediabetes
- Behavior, nutrition, education & exercise

**Guidelines for abstract submission**

- **Language**: English
- **Title**: A concise title with not exceeding 30 words recommended
- **Format**: Objective-Methods-Results-Conclusion
- **Length of body**: 250 words
- **Authors**: Do not include degrees or titles.
- **Contents**: Extremely simple result with comment “The result will be discussed soon” will not be accepted
- **Modification**: Until the deadline for abstract submission
- **Withdrawal**: Written request by email to both diabetes@kams.or.kr (Head secretariat) / icdm@diabetes.or.kr (Joint secretariat) fully required

It is only possible to withdraw an abstract until 30 September 2013. Note that fax submissions will not be accepted.

**Presentation guidelines**

**Registration**

- Authors are asked to make pre-registration for the secretariat to arrange presentation schedule accurately.
- In case of intending to make on-site registration, informing by email in advance is required.
- Not registered author’s paper will be withdrawn by the committee after the registration deadline.

**Speaker’s preview room**

- **Speaker’s preview room hours**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-9 November 2013</td>
<td>Each of the daily schedule; Open 1 hour before start Close 30 minutes after end</td>
</tr>
</tbody>
</table>

- Checking slide deck(s) at the speaker’s preview room is the single most important action you will take to ensure your presentation is a success. It is required to check into the place at least 1 hour before presentation start time.
- Authors should make sure all fonts appear as expected and all sound/video clips are working properly while reviewing presentation slides.
- Note: It is possible to bring your slides onto either USB stick or own laptop having RGB port.

<table>
<thead>
<tr>
<th>Method</th>
<th>USB stick</th>
<th>Own laptop</th>
</tr>
</thead>
<tbody>
<tr>
<td>Format</td>
<td>MS powerpoint only</td>
<td>Not limited</td>
</tr>
<tr>
<td>Cable</td>
<td>Not necessary</td>
<td>RGB cable</td>
</tr>
</tbody>
</table>

**Equipment & software at the preview room**

<table>
<thead>
<tr>
<th>Laptops</th>
<th>OS: MS Windows 7 Software: MS office 2010 / Adobe PDF viewer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cables</td>
<td>‘Mac – RGB’ cable <strong>This is only for authors presenting with their own laptop ‘MAC’ missing their own cable</strong></td>
</tr>
</tbody>
</table>

**Poster exhibition**

- **Date**: 7 – 9 November 2013
- **Place**: Diamond room, Convention center 5F & Hotel lobby 2F, Grand Hilton Seoul Hotel
- **Mounting**: Before 9:00, 7 November 2013
- **Removal**: After 16:00, 9 November 2013
- **Poster size**: 900 mm(W) x 1400 mm(L)
- **Official Language**: English
Travel grant

The ICDM 2013 & 5th AASD offers travel grants to support researchers who want to take part in the conference with gaining experience – abstract submission. The scientific program committee will select recipients for ‘Travel grant’ among outstanding abstract submissions.

- **Eligibility**
  - Foreigners
  - Abstract submission
  - Under the age of 45 years
  - Meeting attendance

- **Funding**
  - The amount: USD 1,000
  - Each recipient will be provided with USD 1,000 in cash at the Korean Diabetes Association’s booth during the meeting.

- **Requirements**
  - Passport
  - Registration

- **Application method & Results**
  - Check the box ‘Apply for Travel Grant’ when submitting the abstract online.
  - The secretariat will send the decision of the program committee by email.

- **Travel Grant Notification (Accept or Decline)**: At the end of September

Accommodation

**Grand Hilton Seoul Hotel**
- Address: 191 HONGJE-DONG, SEOLOMAEUN KU, SEOUL, Seoul, 100-795, SOUTH KOREA

<table>
<thead>
<tr>
<th>Room type</th>
<th>Special rates (Exclusive of VAT &amp; Service Charge)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single</td>
<td>KRW 216,000</td>
</tr>
<tr>
<td>Twin</td>
<td>KRW 216,000</td>
</tr>
<tr>
<td>Double</td>
<td>KRW 216,000</td>
</tr>
<tr>
<td>Executive Floor Room (+1 Breakfast, EFL Lounge Only)</td>
<td>KRW 260,000</td>
</tr>
<tr>
<td>2 Bedroom (2 PAX available)</td>
<td>KRW 282,400</td>
</tr>
<tr>
<td>3 Bedroom (4 PAX available)</td>
<td>KRW 296,000</td>
</tr>
<tr>
<td>4 Bedroom (6 PAX available)</td>
<td>KRW 310,000</td>
</tr>
</tbody>
</table>

**The Plaza Hotel**
- Address: The Plaza 119 Sogong-ro, Jung-gu, Seoul, Korea [100-864]
- [https://www.hoteltheplaza.com/eng/](https://www.hoteltheplaza.com/eng/)

<table>
<thead>
<tr>
<th>Room type</th>
<th>Special rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deluxe</td>
<td>KRW 250,000 / Net</td>
</tr>
<tr>
<td>Premier Suite</td>
<td>KRW 290,000 / Net</td>
</tr>
</tbody>
</table>

**Shinchon Casaville, Seoul**
- Address: 57-26 Nogosan-dong Mapo-gu, Seoul, Korea

<table>
<thead>
<tr>
<th>Room type</th>
<th>Special rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard Double</td>
<td>KRW 85,000</td>
</tr>
<tr>
<td>Standard Twin</td>
<td>KRW 85,000</td>
</tr>
<tr>
<td>Deluxe Double</td>
<td>KRW 95,000</td>
</tr>
<tr>
<td>Superior Family</td>
<td>KRW 110,000</td>
</tr>
</tbody>
</table>

**Other hotels**

<table>
<thead>
<tr>
<th>Hotel</th>
<th>Website</th>
<th>Distance (From the Venue)</th>
<th>Room type</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Westin Chosun Seoul</td>
<td><a href="http://www.echosunhotel.com/Eseoul.action">http://www.echosunhotel.com/Eseoul.action</a></td>
<td>6.78km 25 minutes</td>
<td>Deluxe</td>
</tr>
<tr>
<td>Hotel President</td>
<td><a href="http://www.hotelpresident.co.kr/">http://www.hotelpresident.co.kr/</a></td>
<td>6.63km 18 minutes</td>
<td>Deluxe</td>
</tr>
<tr>
<td>Koreana Hotel</td>
<td><a href="http://www.koreanahotel.com/">http://www.koreanahotel.com/</a></td>
<td>5.81km 16 minutes</td>
<td>Deluxe</td>
</tr>
<tr>
<td>Seoul Royal Hotel</td>
<td><a href="http://www.royal.co.kr">http://www.royal.co.kr</a></td>
<td>6.77km 23 minutes</td>
<td>Deluxe</td>
</tr>
</tbody>
</table>
Incheon International Airport – Venue

**Air Bus**

<table>
<thead>
<tr>
<th>Bus Number</th>
<th># 6005</th>
<th>First Bus</th>
<th>06:15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route Name</td>
<td>Seoul City Hall</td>
<td>Last Bus</td>
<td>22:35</td>
</tr>
<tr>
<td>Bus Type</td>
<td>Limousine (Standard)</td>
<td>Interval</td>
<td>40 minutes</td>
</tr>
<tr>
<td>Travelling Time</td>
<td>90 minutes</td>
<td>Fare</td>
<td>KRW 10,000</td>
</tr>
<tr>
<td>Route</td>
<td>Incheon Int’l Airport -&gt; Soosaek Rail Station -&gt; Moraenae(Cajwa Station) -&gt; Yeonhui Samgeori -&gt; Seoadaemon-Gu Office -&gt; Grand Hilton Hotel</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Taxi**

<table>
<thead>
<tr>
<th>Section</th>
<th>Platform Number</th>
<th>Estimated travel time</th>
<th>Estimated Fare (KRW)</th>
<th>Remark</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard Taxi</td>
<td>6C</td>
<td>45</td>
<td>60,000</td>
<td>24:00 ~ 04:00 additional 20% late night premium.</td>
</tr>
<tr>
<td>Prestige Taxi</td>
<td>8C</td>
<td>45</td>
<td>80,000</td>
<td>Car Phone Service / No late night premium fee.</td>
</tr>
</tbody>
</table>

* Notice : Toll fee (KRW 7,100) will be the passenger’s responsibility. The estimated fare is based on no traffic congestion; the actual rates may vary.

**Hotel Pick-up Service**

It is available for using Grand Hilton Hotel pick-up service. If you want the service, please book in advance through the hotel reservation department.

- Fare : KRW 115,000 for 3 pax including luggage
- Contact Information
  - Tel : +82-2-3216-5656, +82-2-2287-8427~9
  - Email : reservation.grandseoul@hilton.com, grandseoul@hilton.com

Gimpo International Airport – Venue

**Subway**

<table>
<thead>
<tr>
<th>Line</th>
<th>Major stops</th>
<th>Running Hours</th>
<th>Travelling Time (min.)</th>
<th>Fare (KRW)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Airport Railroad (Blue)</td>
<td>Gimpo Int’l Airport -&gt; Digitalmediacity</td>
<td>5:41-24:18</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>*Transfer from Airport Railroad to Line 6 at Digitalmediacity Station.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Line 6 (Dark brown)</td>
<td>Digitalmediacity -&gt; Bulgwang</td>
<td>5:39-24:44</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>*Transfer from Line 6 to Line 3 at Bulgwang Station.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Dark brown)</td>
<td>Bulgwang -&gt; Hongje (Grand Hilton Seoul Hotel) (*Exit no. 4. It is a 15-minute walk from the station to the ICDM 2011 venue.)</td>
<td>5:39-23:59</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Colour</th>
<th>Major stops</th>
<th>Running Hours</th>
<th>Travelling Time (min.)</th>
<th>Fare (KRW)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Airport Railroad</td>
<td>Gimpo Int’l Airport -&gt; Digitalmediacity</td>
<td>5:41-24:18</td>
<td>9</td>
<td></td>
</tr>
</tbody>
</table>

**Bus**

<table>
<thead>
<tr>
<th>Bus Number</th>
<th># 601 -&gt; # 115, # 567, # 815 or # 110A</th>
<th>Travelling Time</th>
<th>70 minutes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route Name</td>
<td>Gwanghwamun</td>
<td>First Bus</td>
<td>04:00</td>
</tr>
<tr>
<td>Bus Type</td>
<td>City Bus</td>
<td>Last Bus</td>
<td>23:10</td>
</tr>
<tr>
<td>Bus Stop Number</td>
<td>4 (1st Floor, Gimpo Int’l Airport)</td>
<td>Interval</td>
<td>Fare</td>
</tr>
<tr>
<td>Route</td>
<td>Gimpo Airport -&gt; Seodaemen Post Office -&gt; Hyundai Apt. (It is a 15-minute walk from the Hyundai Apt. station to the Grand Hilton Seoul Hotel.)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Taxi | In the Gimpo Int’l Airport, there is the short course taxi platform in front of each office building to help people who want to use taxi for a short course. For more information, refer to the following website: http://www.airport.co.kr/doc/gimpo_eng/index.jsp. |

Seoul attractions

**Myeongdong**

Taxi : 26 Mins (4km)
Subway : 21 Mins

Myeongdong Station (Line 4) or Euljiro Il-ga Station (Line 2)
URL : http://english.visitkorea.or.kr/enu/SI/SI_EN_3_1_1_1.jsp?cid=264312

>> Myeongdong is one of the primary shopping districts in Seoul. The two main drags meet in the center of the block with one beginning from Myeongdong Subway Station (Seoul Subway Line No. 4) and the other from Lotte Department Store at Euljiro. Many brand name shops and department stores line the streets and alleys. Common products for sale include clothes, shoes, and accessories. Unlike Namdaemun or Dongdaemun, many designer brands are sold in Myeongdong.

**Itaewon**

Taxi : 31 minutes (9.7km)
Subway : 32 minutes

Itaewon Station / Noksapyeong Station / Hangangjin Station (Line 6)
URL : http://english.visitkorea.or.kr/enu/SI/SI_EN_3_1_1_1.jsp?cid=264358

>> Itaewon is a popular tourist and shopping destination for foreigners who visit Korea. There are over 2,000 stores clustered together with shopping centers, shops selling clothes, shoes, and bags, restaurants, recreation facilities, trading companies, travel agencies, and tourist hotels. The many English signs and many foreigners will make you feel as if you are not in Korea.

**Namdaemun Market**

Taxi : 27 minutes (6.83km)
Subway : 23 minutes

Hoehyeon Station (Line 4)
URL : http://english.visitkorea.or.kr/enu/SH/SH_EN_7_2.jsp?cid=273760

>> Opened in 1964, the Namdaemun Market is the largest traditional market in Korea with various goods in store. All products are sold at affordable prices and the stores in this area also function as a wholesale markets.
2013 International Conference on Diabetes and Metabolism & 5th Asian Association for the Study of Diabetes